Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225.

ABSTRACT:

Background

PSMA-TO-1 ("Tumor-Optimized-1") is a novel PSMA ligand with longer circulation time than PSMA-617. We compared the biodistribution in subcutaneous tumor-bearing mice of PSMA-TO-1, PSMA-617 and PSMA-11 when labeled with ⁶⁸Ga and ¹⁷⁷Lu, and the survival after treatment with ²²⁵Ac-PSMA-TO-1/-617 in a murine model of disseminated prostate cancer. We also report dosimetry data of ¹⁷⁷Lu-PSMA-TO1/-617 in prostate cancer patients.

Methods

First, PET images of ⁶⁸Ga-PSMA-TO-1/-617/-11 were acquired on consecutive days in three mice bearing subcutaneous C4-2 xenografts. Second, 50 subcutaneous tumor-bearing mice received either 30 MBq of ¹⁷⁷Lu-PSMA-617 or ¹⁷⁷Lu-PSMA-TO-1 and were sacrificed at 1, 4,

SUBMITTER: Meyer C 

PROVIDER: S-EPMC9526774 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature